CN1853729A - 多核的氢氧化铁-糖复合物的制备方法 - Google Patents
多核的氢氧化铁-糖复合物的制备方法 Download PDFInfo
- Publication number
- CN1853729A CN1853729A CNA2005100254174A CN200510025417A CN1853729A CN 1853729 A CN1853729 A CN 1853729A CN A2005100254174 A CNA2005100254174 A CN A2005100254174A CN 200510025417 A CN200510025417 A CN 200510025417A CN 1853729 A CN1853729 A CN 1853729A
- Authority
- CN
- China
- Prior art keywords
- multinuclear
- ferric oxide
- hydroxide
- iron
- hydrated ferric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 36
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title abstract description 53
- 229910052742 iron Inorganic materials 0.000 title abstract description 11
- 239000002131 composite material Substances 0.000 title 1
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 23
- 239000007864 aqueous solution Substances 0.000 claims abstract description 17
- 239000012670 alkaline solution Substances 0.000 claims abstract description 9
- LDHBWEYLDHLIBQ-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide;hydrate Chemical compound O.[OH-].[O-2].[Fe+3] LDHBWEYLDHLIBQ-UHFFFAOYSA-M 0.000 claims description 45
- 238000006243 chemical reaction Methods 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 24
- 239000005720 sucrose Substances 0.000 claims description 20
- 229930006000 Sucrose Natural products 0.000 claims description 19
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 13
- 239000003513 alkali Substances 0.000 claims description 9
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 6
- -1 alkali-metal bicarbonate Chemical class 0.000 claims description 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 6
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 5
- 150000002505 iron Chemical class 0.000 claims description 5
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 150000002772 monosaccharides Chemical group 0.000 claims description 5
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 5
- 108010001394 Disaccharidases Proteins 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 4
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 3
- 229910000358 iron sulfate Inorganic materials 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 235000014413 iron hydroxide Nutrition 0.000 abstract 2
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000047 product Substances 0.000 description 21
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 4
- 238000005227 gel permeation chromatography Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940035081 venofer Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010027540 Microcytosis Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004887 ferric hydroxide Drugs 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
实施例 | 制备氢氧化铁的温度(℃) | 重均分子量 | 等电点 | 铁糖质量比率% | 铁含量% |
2 | 5 | 24000 | 4.8 | 1∶15 | 5.2 |
3 | 10 | 30000 | 4.7 | 1∶14 | 5.6 |
4 | 15 | 48000 | 5.0 | 1∶15.5 | 6 |
5 | 20 | 80000 | 4.5 | 1∶16 | 5 |
6 | 25 | 150000 | 4.6 | 1∶17 | 5.3 |
实施例 | 滴加时间(分钟) | 制备氢氧化铁的温度(℃) | 铁糖反应的温度(℃) | 重均分子量(道尔顿) | 铁糖反应的时间(小时) | 等电点 |
7 | 32 | 15±2 | 80 | 54000 | 36 | 5.8 |
8 | 30 | 15±2 | 100 | 50000 | 36 | 5.4 |
9 | 30 | 15±2 | 110 | 48000 | 16 | 4.8 |
10 | 31 | 15±2 | 120 | 47000 | 13 | 4.7 |
Claims (15)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100254174A CN100528237C (zh) | 2005-04-26 | 2005-04-26 | 多核的氢氧化铁-糖复合物的制备方法 |
ES06722307T ES2392453T3 (es) | 2005-04-26 | 2006-04-12 | Procedimiento para la preparación de complejos polinucleares de hidróxido férrico-sacárido |
PCT/CN2006/000655 WO2006114040A1 (fr) | 2005-04-26 | 2006-04-12 | Preparation de complexes multinucleaires ferriques-saccharidiques |
US11/911,449 US8053470B2 (en) | 2005-04-26 | 2006-04-12 | Process for the preparation of polynuclear ferric hydroxide-saccaride complexes |
EP06722307A EP1876187B1 (en) | 2005-04-26 | 2006-04-12 | Process for the preparation of polynuclear ferric hydroxide-saccharide complexes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100254174A CN100528237C (zh) | 2005-04-26 | 2005-04-26 | 多核的氢氧化铁-糖复合物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1853729A true CN1853729A (zh) | 2006-11-01 |
CN100528237C CN100528237C (zh) | 2009-08-19 |
Family
ID=37194377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100254174A Active CN100528237C (zh) | 2005-04-26 | 2005-04-26 | 多核的氢氧化铁-糖复合物的制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8053470B2 (zh) |
EP (1) | EP1876187B1 (zh) |
CN (1) | CN100528237C (zh) |
ES (1) | ES2392453T3 (zh) |
WO (1) | WO2006114040A1 (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103059072A (zh) * | 2013-01-18 | 2013-04-24 | 常州工程职业技术学院 | 一种绿色环保的蔗糖铁原料药的制备方法 |
CN103626807A (zh) * | 2013-11-20 | 2014-03-12 | 青岛国风药业股份有限公司 | 一种多糖铁复合物的制备方法及其质量检测方法 |
CN104177505A (zh) * | 2013-05-24 | 2014-12-03 | 重庆圣华曦药业股份有限公司 | 一种分离和纯化多糖铁复合物的方法 |
CN106176808A (zh) * | 2010-10-19 | 2016-12-07 | 长春纳米生技公司 | 金属离子纳米簇组合物 |
CN108752395A (zh) * | 2009-03-25 | 2018-11-06 | 法码科思莫斯控股有限公司 | 稳定的铁寡糖复合物 |
CN112156109A (zh) * | 2020-09-29 | 2021-01-01 | 神奈纳米医药技术(珠海)有限公司 | 氢氧化铁-糖络合物的制备方法及其应用 |
CN112694511A (zh) * | 2020-12-23 | 2021-04-23 | 福建呈睿医药科技有限公司 | 一种多糖铁复合物、胶囊制剂的制备方法和质量控制方法 |
CN114249844A (zh) * | 2021-10-13 | 2022-03-29 | 重庆朋辉化工产品有限公司 | 一种分子量可控的多聚糖铁及其制备方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009248885B2 (en) * | 2008-05-23 | 2015-02-05 | Hospira, Inc. | Packaged iron sucrose products |
US8536106B2 (en) | 2010-04-14 | 2013-09-17 | Ecolab Usa Inc. | Ferric hydroxycarboxylate as a builder |
US9370202B2 (en) | 2013-03-15 | 2016-06-21 | LG Bionano, LLC | Encapsulated metal ion nanoclusters |
US20180147238A1 (en) * | 2015-05-29 | 2018-05-31 | Sun Pharmaceutical Industries Ltd. | Composition of iron sucrose and process for its preparation |
PT3930686T (pt) | 2019-02-28 | 2023-09-04 | Renibus Therapeutics Inc | Novas composições de ferro e métodos de preparação e utilização das mesmas |
AU2021351482A1 (en) * | 2020-09-29 | 2023-03-23 | Lg Bionano Co. Ltd | Methods of preparing iron complexes |
US20230084291A1 (en) | 2021-08-27 | 2023-03-16 | American Regent, Inc. | Iron compositions and methods of making and using them |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES360433A1 (es) * | 1968-11-20 | 1970-11-16 | Rocador Sa | Procedimiento para la fabricacion de un compuesto de hierrotrivalente apropiado para administracion por via oral. |
US3686397A (en) * | 1970-05-18 | 1972-08-22 | Mueller Arthur | Parenteral iron preparations |
DE3844065A1 (de) * | 1988-12-28 | 1990-07-05 | Orgaplan Gmbh | Glycosidische eisen-ii- und eisen-iii-komplexzubereitungen und ihre verwendung |
CN1097989A (zh) | 1993-12-27 | 1995-02-01 | 广东太阳神集团有限公司 | 蔗糖铁、其制备方法及其制剂 |
IN187116B (zh) | 2000-01-31 | 2002-02-09 | Alkem Lab | |
WO2002056826A2 (en) * | 2000-11-02 | 2002-07-25 | Chromaceutical Advanced Technologies, Inc. | Method for producing purified hematinic iron-saccharidic complex and product produced |
RU2198665C1 (ru) | 2001-12-27 | 2003-02-20 | Общество с ограниченной ответственностью Фирма "А-БИО" | Способ получения железосодержащего лекарственного средства |
US6693211B2 (en) * | 2002-05-15 | 2004-02-17 | Geneva Pharmaceuticals, Inc. | Chemical process |
US7964568B2 (en) * | 2003-05-30 | 2011-06-21 | Chromaceutical Advanced Technologies, Inc. | Synthesis of high molecular weight iron-saccharidic complexes |
AU2004317858B2 (en) | 2004-03-16 | 2011-04-21 | Navinta, Llc | Iron sucrose complexes and method of manufacture thereof |
WO2005116046A1 (de) | 2004-05-24 | 2005-12-08 | Cilag Ag | Verfahren zur herstellung von eisensaccharosekomplex |
DE05783995T1 (de) | 2004-07-14 | 2007-10-11 | Shasun Chemicals and Drugs Ltd., Chennai | Verbessertes verfahren zur herstellung von form i aus olanzapin |
-
2005
- 2005-04-26 CN CNB2005100254174A patent/CN100528237C/zh active Active
-
2006
- 2006-04-12 ES ES06722307T patent/ES2392453T3/es active Active
- 2006-04-12 WO PCT/CN2006/000655 patent/WO2006114040A1/zh not_active Application Discontinuation
- 2006-04-12 EP EP06722307A patent/EP1876187B1/en not_active Not-in-force
- 2006-04-12 US US11/911,449 patent/US8053470B2/en not_active Expired - Fee Related
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108752395A (zh) * | 2009-03-25 | 2018-11-06 | 法码科思莫斯控股有限公司 | 稳定的铁寡糖复合物 |
CN106176808A (zh) * | 2010-10-19 | 2016-12-07 | 长春纳米生技公司 | 金属离子纳米簇组合物 |
CN103059072A (zh) * | 2013-01-18 | 2013-04-24 | 常州工程职业技术学院 | 一种绿色环保的蔗糖铁原料药的制备方法 |
CN103059072B (zh) * | 2013-01-18 | 2015-08-26 | 常州工程职业技术学院 | 一种绿色环保的蔗糖铁原料药的制备方法 |
CN104177505A (zh) * | 2013-05-24 | 2014-12-03 | 重庆圣华曦药业股份有限公司 | 一种分离和纯化多糖铁复合物的方法 |
CN103626807A (zh) * | 2013-11-20 | 2014-03-12 | 青岛国风药业股份有限公司 | 一种多糖铁复合物的制备方法及其质量检测方法 |
CN112156109A (zh) * | 2020-09-29 | 2021-01-01 | 神奈纳米医药技术(珠海)有限公司 | 氢氧化铁-糖络合物的制备方法及其应用 |
CN112694511A (zh) * | 2020-12-23 | 2021-04-23 | 福建呈睿医药科技有限公司 | 一种多糖铁复合物、胶囊制剂的制备方法和质量控制方法 |
CN114249844A (zh) * | 2021-10-13 | 2022-03-29 | 重庆朋辉化工产品有限公司 | 一种分子量可控的多聚糖铁及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2006114040A1 (fr) | 2006-11-02 |
EP1876187A4 (en) | 2010-05-12 |
EP1876187A1 (en) | 2008-01-09 |
CN100528237C (zh) | 2009-08-19 |
ES2392453T3 (es) | 2012-12-10 |
EP1876187B1 (en) | 2012-09-26 |
US20080176941A1 (en) | 2008-07-24 |
US8053470B2 (en) | 2011-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1853729A (zh) | 多核的氢氧化铁-糖复合物的制备方法 | |
JP5426010B2 (ja) | 安定な鉄オリゴ糖化合物 | |
NZ578457A (en) | Iron-carbohydrate complex compounds containing at least 2% iron(II) | |
US2437518A (en) | Manufacture of infusion and injection fluids | |
CN1931866A (zh) | 一种秸秆生产木糖的工艺 | |
US3928581A (en) | Certain polymer-iron complexes for treatment of iron deficiency | |
NO125096B (zh) | ||
CZ20003535A3 (cs) | Sloučenina železa a dextranu | |
JP2018100424A (ja) | ヒドロキシエチル澱粉誘導体の製造方法 | |
US8383808B2 (en) | Method to prepare D-glucosamine hydrochloride | |
CN108129582A (zh) | 一种铁碳水化合物复合物的制备方法 | |
TWI672146B (zh) | 新化學修飾肝素及其製造方法 | |
CN101215338B (zh) | 异麦芽低聚糖铁及其制备方法 | |
CN1074762C (zh) | L-苏糖酸铬盐、其制备方法及其应用 | |
CN1876186A (zh) | 一种内皮抑素结合物及其制备方法 | |
US20100167984A1 (en) | Complex between human insulin and an amphiphilic polymer and use of this complex in the preparation of a fast-acting human insulin formulation | |
CN114262387B (zh) | 一种抗性糊精的制备方法 | |
CN105237974A (zh) | 一种原位聚合pla/mmt降解增强母料及其制备方法 | |
CN1844137A (zh) | 氨基葡萄糖酸铬制备方法及其用途 | |
CN1864666A (zh) | 甲磺酸左氧氟沙星冻干粉针注射剂及其制备方法 | |
EP2580227B1 (en) | New low molecular weight complexes between iron and maltobionic acid, use thereof for intramuscular or subcutaneous administration in the treatment of anemic states, and new pharmaceutical compositions adapted for these uses | |
CN112300299A (zh) | 一种锌、钙多糖配合物的制备方法和应用 | |
CN1830426A (zh) | 一种新鱼腥草素钠注射液及其制备方法和用途 | |
CN110878129A (zh) | 一种氨基葡萄糖肝素盐及其应用 | |
CN1208351C (zh) | 纳米晶体纤维素-肝素复合物及其制法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPME |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20110817 Address after: 400061 No. 565, Tu Shan Road, Nan'an District, Chongqing Co-patentee after: Shanghai FOSUN Pharmaceutical Co.,Ltd. Patentee after: Chongqing Pharmaceutical Research Institute Co., Ltd. Address before: 400061 No. 565, Tu Shan Road, Nan'an District, Chongqing Patentee before: Chongqing Pharmaceutical Research Institute Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190201 Address after: 401221 No. 2 Yanjiahua South Third Branch Road, Changshou District, Chongqing Co-patentee after: Chongqing Pharmaceutical Research Institute Co., Ltd. Patentee after: Chongqing Medical Institute Pharmaceutical Co., Ltd. Co-patentee after: Shanghai FOSUN Pharmaceutical Co.,Ltd. Address before: 400061 Tu Shan Road, South Bank district, Chongqing, No. 565 Co-patentee before: Shanghai FOSUN Pharmaceutical Co.,Ltd. Patentee before: Chongqing Pharmaceutical Research Institute Co., Ltd. Effective date of registration: 20190201 Address after: 401221 No. 2 Yanjiahua South Third Branch Road, Changshou District, Chongqing Co-patentee after: Chongqing Pharmaceutical Research Institute Co., Ltd. Patentee after: Chongqing Medical Institute Pharmaceutical Co., Ltd. Co-patentee after: Shanghai FOSUN Pharmaceutical Co.,Ltd. Address before: 400061 Tu Shan Road, South Bank district, Chongqing, No. 565 Co-patentee before: Shanghai FOSUN Pharmaceutical Co.,Ltd. Patentee before: Chongqing Pharmaceutical Research Institute Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200519 Address after: 401221, No. 3, No. 1 South Road, Changshou chemical industry park, Chongqing Co-patentee after: CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Patentee after: CHONGQING CARELIFE PHARMACEUTICAL Co.,Ltd. Co-patentee after: SHANGHAI FOSUN PHARMACEUTICAL DEVELOPMENT Co.,Ltd. Address before: 401221 No. 2 Yanjiahua South Third Branch Road, Changshou District, Chongqing Co-patentee before: CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Patentee before: Chongqing Medical Institute Pharmaceutical Co., Ltd. Co-patentee before: SHANGHAI FOSUN PHARMACEUTICAL DEVELOPMENT Co.,Ltd. |
|
TR01 | Transfer of patent right |